266 related articles for article (PubMed ID: 26151293)
1. MPLA incorporation into DC-targeting glycoliposomes favours anti-tumour T cell responses.
Boks MA; Ambrosini M; Bruijns SC; Kalay H; van Bloois L; Storm G; Garcia-Vallejo JJ; van Kooyk Y
J Control Release; 2015 Oct; 216():37-46. PubMed ID: 26151293
[TBL] [Abstract][Full Text] [Related]
2. In situ Delivery of Tumor Antigen- and Adjuvant-Loaded Liposomes Boosts Antigen-Specific T-Cell Responses by Human Dermal Dendritic Cells.
Boks MA; Bruijns SCM; Ambrosini M; Kalay H; van Bloois L; Storm G; Gruijl T; van Kooyk Y
J Invest Dermatol; 2015 Nov; 135(11):2697-2704. PubMed ID: 26083554
[TBL] [Abstract][Full Text] [Related]
3. Glycan-modified liposomes boost CD4+ and CD8+ T-cell responses by targeting DC-SIGN on dendritic cells.
Unger WW; van Beelen AJ; Bruijns SC; Joshi M; Fehres CM; van Bloois L; Verstege MI; Ambrosini M; Kalay H; Nazmi K; Bolscher JG; Hooijberg E; de Gruijl TD; Storm G; van Kooyk Y
J Control Release; 2012 May; 160(1):88-95. PubMed ID: 22366522
[TBL] [Abstract][Full Text] [Related]
4. Cross-presentation through langerin and DC-SIGN targeting requires different formulations of glycan-modified antigens.
Fehres CM; Kalay H; Bruijns SC; Musaafir SA; Ambrosini M; van Bloois L; van Vliet SJ; Storm G; Garcia-Vallejo JJ; van Kooyk Y
J Control Release; 2015 Apr; 203():67-76. PubMed ID: 25656175
[TBL] [Abstract][Full Text] [Related]
5. In situ Delivery of Antigen to DC-SIGN(+)CD14(+) Dermal Dendritic Cells Results in Enhanced CD8(+) T-Cell Responses.
Fehres CM; van Beelen AJ; Bruijns SCM; Ambrosini M; Kalay H; Bloois LV; Unger WWJ; Garcia-Vallejo JJ; Storm G; de Gruijl TD; Kooyk YV
J Invest Dermatol; 2015 Sep; 135(9):2228-2236. PubMed ID: 25885805
[TBL] [Abstract][Full Text] [Related]
6. Targeting glycan modified OVA to murine DC-SIGN transgenic dendritic cells enhances MHC class I and II presentation.
Singh SK; Stephani J; Schaefer M; Kalay H; García-Vallejo JJ; den Haan J; Saeland E; Sparwasser T; van Kooyk Y
Mol Immunol; 2009 Dec; 47(2-3):164-74. PubMed ID: 19818504
[TBL] [Abstract][Full Text] [Related]
7. Incorporation of Toll-Like Receptor Ligands and Inflammasome Stimuli in GM3 Liposomes to Induce Dendritic Cell Maturation and T Cell Responses.
Nijen Twilhaar MK; Czentner L; Bouma RG; Olesek K; Grabowska J; Wang AZ; Affandi AJ; Belt SC; Kalay H; van Nostrum CF; van Kooyk Y; Storm G; den Haan JMM
Front Immunol; 2022; 13():842241. PubMed ID: 35251040
[TBL] [Abstract][Full Text] [Related]
8. Glycan modification of the tumor antigen gp100 targets DC-SIGN to enhance dendritic cell induced antigen presentation to T cells.
Aarnoudse CA; Bax M; Sánchez-Hernández M; García-Vallejo JJ; van Kooyk Y
Int J Cancer; 2008 Feb; 122(4):839-46. PubMed ID: 17957800
[TBL] [Abstract][Full Text] [Related]
9. Glycan-based DC-SIGN targeting vaccines to enhance antigen cross-presentation.
van Kooyk Y; Unger WW; Fehres CM; Kalay H; García-Vallejo JJ
Mol Immunol; 2013 Sep; 55(2):143-5. PubMed ID: 23158834
[TBL] [Abstract][Full Text] [Related]
10. Lipo-Based Vaccines as an Approach to Target Dendritic Cells for Induction of T- and iNKT Cell Responses.
Stolk DA; de Haas A; Vree J; Duinkerken S; Lübbers J; van de Ven R; Ambrosini M; Kalay H; Bruijns S; van der Vliet HJ; de Gruijl TD; van Kooyk Y
Front Immunol; 2020; 11():990. PubMed ID: 32536918
[TBL] [Abstract][Full Text] [Related]
11. Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer.
Jasani B; Navabi H; Adams M
Vaccine; 2009 May; 27(25-26):3401-4. PubMed ID: 19200817
[TBL] [Abstract][Full Text] [Related]
12. Glyco-Dendrimers as Intradermal Anti-Tumor Vaccine Targeting Multiple Skin DC Subsets.
Duinkerken S; Horrevorts SK; Kalay H; Ambrosini M; Rutte L; de Gruijl TD; Garcia-Vallejo JJ; van Kooyk Y
Theranostics; 2019; 9(20):5797-5809. PubMed ID: 31534520
[TBL] [Abstract][Full Text] [Related]
13. Comparison of antibodies and carbohydrates to target vaccines to human dendritic cells via DC-SIGN.
Cruz LJ; Tacken PJ; Pots JM; Torensma R; Buschow SI; Figdor CG
Biomaterials; 2012 Jun; 33(16):4229-39. PubMed ID: 22410170
[TBL] [Abstract][Full Text] [Related]
14. Liposomes-coated gold nanocages with antigens and adjuvants targeted delivery to dendritic cells for enhancing antitumor immune response.
Liang R; Xie J; Li J; Wang K; Liu L; Gao Y; Hussain M; Shen G; Zhu J; Tao J
Biomaterials; 2017 Dec; 149():41-50. PubMed ID: 28992509
[TBL] [Abstract][Full Text] [Related]
15. Mouse DC-SIGN/CD209a as Target for Antigen Delivery and Adaptive Immunity.
Schetters STT; Kruijssen LJW; Crommentuijn MHW; Kalay H; Ochando J; den Haan JMM; Garcia-Vallejo JJ; van Kooyk Y
Front Immunol; 2018; 9():990. PubMed ID: 29867967
[TBL] [Abstract][Full Text] [Related]
16. Immunity by formulation design: induction of high CD8+ T-cell responses by poly(I:C) incorporated into the CAF01 adjuvant via a double emulsion method.
Nordly P; Rose F; Christensen D; Nielsen HM; Andersen P; Agger EM; Foged C
J Control Release; 2011 Mar; 150(3):307-17. PubMed ID: 21111765
[TBL] [Abstract][Full Text] [Related]
17. Targeting dendritic cells with antigen-containing liposomes: a highly effective procedure for induction of antitumor immunity and for tumor immunotherapy.
van Broekhoven CL; Parish CR; Demangel C; Britton WJ; Altin JG
Cancer Res; 2004 Jun; 64(12):4357-65. PubMed ID: 15205352
[TBL] [Abstract][Full Text] [Related]
18. An allergen-fused dendritic cell-binding peptide enhances in vitro proliferation of equine T-cells and cytokine production.
Ziegler A; Olzhausen J; Hamza E; Stojiljkovic A; Stoffel MH; Garbani M; Rhyner C; Marti E
Vet Immunol Immunopathol; 2022 Jan; 243():110351. PubMed ID: 34800874
[TBL] [Abstract][Full Text] [Related]
19. In vivo targeting of human DC-SIGN drastically enhances CD8⁺ T-cell-mediated protective immunity.
Hesse C; Ginter W; Förg T; Mayer CT; Baru AM; Arnold-Schrauf C; Unger WW; Kalay H; van Kooyk Y; Berod L; Sparwasser T
Eur J Immunol; 2013 Oct; 43(10):2543-53. PubMed ID: 23784881
[TBL] [Abstract][Full Text] [Related]
20. Dual TLR agonist nanodiscs as a strong adjuvant system for vaccines and immunotherapy.
Kuai R; Sun X; Yuan W; Ochyl LJ; Xu Y; Hassani Najafabadi A; Scheetz L; Yu MZ; Balwani I; Schwendeman A; Moon JJ
J Control Release; 2018 Jul; 282():131-139. PubMed ID: 29702142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
